Restoration of PKM1 improves functional maturation of human stem-cell derived-β cell by regulating PEP metabolism

12/21/25

Altered B cell metabolic pathways characterize T1D progression (bioRxiv 7/24)

12/27/25

sc-RNA-seq analysis of longitudinal CD4+ T cell samples reveals cell-type-specific changes during early stages of T1D                  

12/29/25

Synergistic Effect of 3D Culture and a Pancreatic Tissue-Derived ECM on Efficient Differentiation of WJ-MSCs into Pancreatic Islet-like Cells            

12/17/25

Comparative β-cell development: insights from Rodents, humans and induced pluripotent stem cell models

12/18/25

CD168 Identifies Proliferating Pancreatic Islet Cells in Murine and Human      

12/21/25

Protective IFIH1 variant reduces immune-mediated islet stress and dysfunction in a T1D genetic background                   

12/31/25

Beta hydroxybutyrate alters beta cell identity and function in human islets                                    

12/26/25

Influence of Protein Carbonylation and Crosslinking in Insulin Secretion and Pre-Type 1 Diabetes (thesis)                     

2025

Characterisation of human pancreatic mesenchymal stromal cells in type 1 diabetes                                

12/21/25

Quantitative V-gene-targeted T cell receptor sequencing as a biomarker in T1D

12/18/25

Gamma Irradiation of Poly(lactide-co-glycolide) Scaffolds Reduces the Mechanical Stability and Function of Islet Grafts in Diabetic NHP

12/24/25

Antigen-Specific Chimeric Antigen Receptor-T Regulatory Cells Home to Human Islets, Suppress Cytotoxic T Lymphocytes and Reverse T1D                     

12/22/25

Mitochondrial position responds to glucose stimulation in a model of the pancreatic beta cell         

12/18/25

Changes in circulating NK and innate-like T cells in type 1 and type 2 diabetes

12/3/25

Loss of Exocytosis Protein DOC2B is an Early Event in Type 1 Diabetes Development                                           

12/29/25

A stem cell knockout village reveals lineage rewiring and a non-canonical islet cell fate in monogenic diabetes

12/25/25

Insulin-Degrading Enzyme is a modulator of pancreatic beta-cell function vis primary cilium and cytoskeletal dynamics (thesis)

2025

Islet amyloid disrupts MHC class II antigen presentation and delays autoimmune diabetes in NOD mice              

12/22/25

Free-floating Long-term Vascularized Mesenchymal Organoids                   

12/26/25

Functional Survival of Human sc- Islets Microencapsulated With Alginate Incorporating CXCL12 in NHP Without Systemic Immunosuppression

12/22/25

Acute and resolving inflammation differentially regulates beta cell function in mice via interactions between peritoneal and islet-associated macrophages

12/26/25

Functionalized peptide hydrogel to generate human insulin-producing cells in vitro                    

12/23/25

TAS1R3 influences GTPase-dependent signaling in human islet β-cells            

12/7/25

Small non-coding RNA profiling reveals inflammatory and mitochondrial related changes in aging β-cells and islet macrophages

12/18/25

Role of small intronic RNAs in the crosstalk between immune cells and beta-cells during T1D development        

12/29/25

Real-world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement                 

12/22/25

Interoceptive Awareness Moderates the Relationship Between Hypoglycemia Exposure and Symptom Recognition in Adults With Type 1 Diabetes       

12/30/25

Effect of Semaglutide on Insulin Dose Reduction in Adults With T1D and Obesity Using AID Systems      

12/22/25

What is the impact of an advanced hybrid closed-loop system on weight control among people with type 1 diabetes?

12/28/25

Sex Differences in Continuous Glucose Monitoring Metrics and Glucose Variability in Subjects with T1D Treated with Advanced HCL                    

12/13/25

Proliferative Diabetic Retinopathy in Young-Onset Type 1 Diabetes in Croatia: Risk Factors and a Predictive Economic Model for National Screening

12/3/25

Obesity and overweight-related differences in cardiometabolic risk factors in type 1 diabetes             

12/22/25

Evaluation of dental ages of children with type I diabetes using different dental age estimation methods: a retrospective cohort study

12/24/25

GIP reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with T1D-RCT

12/28/25

Outcomes of insulin treatment using an AID from the onset of T1D in pediatric patients-A 1-year retrospective, observational, two-center study

12/24/25

All-Cause Mortality and Health Care Resource Utilization in Patients with T1D Treated with GLP1 RA/GIP

12/22/25

Combining GLP-1 analogues with SGLT2 inhibitors to treat patients with T1D,BMI > 25 kg/m2, and CKD - RCT        

12/21/25

Performance of three simultaneously used CGMs around a physically active weekend camp in adults with T1D: A prospective lab and real-world study   

12/19/25

Perspectives of parents receiving normal results from genomic newborn screening: a mixed-methods evaluation from the early check program         

12/2/25

Twenty-Five Hours of Fasting with Automated Insulin Delivery in Youth with Type 1 Diabetes                

12/22/25

Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes                

12/22/25

User evaluation of the Hypo-METRICS app: A tool for real-time symptom reporting of hypoglycaemia           

12/30/25

Safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump in adults and adolescents with type 1 diabetes mellitus. The SP8 trial       

12/26/25

Is Diabetes Technology Associated With Weight Gain in Children and Adolescents With Type 1 Diabetes?  

12/24/25

In-flight glycaemic control using automated insulin delivery systems: A within-subject comparative pilot study  

12/22/25

Time in Tight Range Versus Time in Range for Predicting Diabetic Retinopathy in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections

12/11/25

Comparison of demographics and treatment outcome in children with T1D related to the economic background of their country of residence           

12/22/25

Exogenous Insulin Antibody Syndrome and Subsequent Severe Subcutaneous Insulin Resistance Complicating T1D

12/30/25

Clustering patterns in Finnish type 1 diabetes patients: a nationwide register-based study                              

12/30/25

Pediatric reference values for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon in children and adolescents

12/23/25

Age-related heterogeneity of T1D in children: a single-center retrospective study

12/27/25

SPOmiAlign: A modality-agnostic framework for robust and scalable spatial multimodal alignment via feature matching

12/22/25

Dietary intake of vitamins A, B, C, D and E and risk of islet autoimmunity andT1D in genetically at-risk children: DIPP

12/19/25

The efficacy of CGM driven machine learning algorithms in predicting hypoglycemia in patients with T1DM: a systematic review and meta-analysis              

12/17/25

Genetic risk in extremely early onset type 1 diabetes                            

12/19/25

Interaction Between CTLA-4, FOXO-3, and PTPN-22Variants and Environmental Factors in T1D-Observational Association Study

12/12/25

Druggable targets and immunological mechanisms for T1D treatment: Genetic evidence from multi-omics Mendelian randomization combined with meta-analysis     

12/21/25

Tandem repeat variation shapes immune cell type-specific gene expression         

12/23/25

Tertiary lymphoid structure drives allograft rejection via IFN-γ-JAK-STAT-dependent atypical memory B cell differentiation    

12/10/25

Phosphodiesterase ENPP2, which is co-upregulated in obese and pregnant mice, is essential for islet beta cell compensation during obesity

12/26/25

"Live" cell shipment-a forward-looking transport option for cryo-sensitive cell-based therapies                                            

12/8/25

Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced Patients

12/25/25

IL-36 mediates immune activation in Sjögren's disease and may represent a novel biomarker of disease              

12/22/25

Single-cell landscape of immune cells in multiple autoimmune diseases                                                     

12/19/25

Clarifying the Link Between Autoimmune Disease and Cancer Using Existing RNA-Seq Data (thesis)

2025

Modeling Immune Lineage Co-Development in Human Pluripotent Stem Cell-derived Liver Organoids                                 

12/16/25

The Trm-Treg Axis as a tissue-encoded immune checkpoint in chronic inflammation and autoimmunity                                         

12/26/25

Autoimmune HLA Alleles and Neoantigens Predict Myelodysplastic Syndrome Outcomes after Allogeneic HSCT: A CIBMTR Analysis                  

12/18/25

Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents                            

12/1/25

Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China

12/20/25

Single cell and spatial characterization of the human pancreas reveals drivers of beta cell dysfunction in cystic fibrosis

12/16/25

Spatially patterned kidney assembloids recapitulate progenitor self-assembly and enable high-fidelity in vivo disease modeling

10/2/25

Association of endocrine autoantibodies (anti-TPO, anti-GAD, anti-insulin) with histopathological severity in pediatric Celiac disease   

12/22/25

The Role of the Autoimmune Regulator Gene in the Control of MHC II Antigen-Processing and Presentation by Medullary Thymic Epithelial Cells

12/25/25

Is a Functional Cure Possible in Autoimmune Diseases? Evidence from Trigger Eradication, Transplantation, and Cellular Therapies       

12/23/25

Advances in lipid nanoparticle delivery systems for targeted cytokine immunotherapy in autoimmune disorders       

12/23/25

Genetic and environmental imprints on T cell receptor repertoires as predictors of graft-versus-host disease              

12/25/25

Genetic engineering approaches in stem and somatic cells for the generation of insulin-producing β-cells

12/20/25

Metabolic Stress and Adaptation in Pancreatic β-Cells to Hypoxia: Mechanisms, Modulators, and Implications for Transplantation    

12/17/25

(TCRαβ+) Double-Negative T Cells in Type 1 Diabetes Mellitus                        

12/29/25

Macrophages as central mediators of sympathetic neuro-immune interplay in autoimmunity            

12/15/25

The Role of TRPV1 in Type 1 Diabetes                       

12/18/25

Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an internatio...

12/17/25

Compartmentalized nutrient and hormone sensing in β-cells: the role of cilia                            

12/23/25

Designs of the clinical trials aiming at evaluating cell and gene therapy products - A critical appraisal from a literature review

12/26/25

Molecular Mimicry at the Gut-Immune Interface: A Mechanistic Link to Type 1 Diabetes

12/29/25

Metabolic regulation of regulatory T cells: mechanisms, heterogeneity, and implications in disease

12/11/25

Grants under threat at the US National Institutes of Health

12/20/25

Understanding Pancreatic Islet Stress Responses and Developing Strategies to Improve Transplantation Grafts (thesis)                                                      

2025

Metabolic and immune dysfunction at the crossroads between type 1 diabetes and neurodegeneration        

12/17/25

My cells, my model: immune-competent autologous organ-on-chip systems as a new paradigm in precision medicine                     

12/11/25

Macrophages: friend or foe in diabetes pathogenesis and therapy                     

12/14/25

Harnessing the immunomodulatory properties of HLA-G for advanced immunotherapies                  

12/8/25

WHAT WILL BE THE FIRST AI-DESIGNED DRUG?                   

12/9/25

Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance

‘California’ brand insulin is hitting the market

FDA Explores New Contracting Approach to Advance Public Health Innovation